Immunotherapy treatments use parts of a person’s immune system to fight disease. In the recent past, immunotherapy has become an important part of treating some types of cancer e.g. melanoma, NSCLC. Studies of these treatments have resulted in a number of observations that have implications for the statistician e.g. delayed treatment effects, long term survivors etc. This joint Basel Biometric Society / PSI one day meeting will present an overview of the science and potential statistical challenges across a range of topics covering early and late phases of development, regulatory and health technology assessments. The speakers from Academia, Regulatory Bodies and Pharma will share their thoughts, ideas and experiences, including case studies. There will be plenty of time for questions and interactions with colleagues.
The meeting will take place on June 15th 2017 in Basel at the Roche IT Centre. Further details on the agenda will follow but for now…please save the date!
If you have any questions please feel free to contact one of the organisers from the BBS or PSI Scientific Committee: firstname.lastname@example.org, email@example.com or firstname.lastname@example.org